Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076) Net Income From Continuing Operations : ¥165 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Sinopep Allsino Bio Pharmaceutical Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Sinopep Allsino Bio Pharmaceutical Co's net income from continuing operations for the three months ended in Dec. 2023 was ¥75 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was ¥165 Mil.

Sinopep Allsino Bio Pharmaceutical Co Net Income From Continuing Operations Historical Data

The historical data trend for Sinopep Allsino Bio Pharmaceutical Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinopep Allsino Bio Pharmaceutical Co Net Income From Continuing Operations Chart

Sinopep Allsino Bio Pharmaceutical Co Annual Data

Trend

Dec13

Dec14

Dec15

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

44.81

120.03

108.81

122.77

165.45

Sinopep Allsino Bio Pharmaceutical Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Income From Continuing Operations	Get a 7-Day Free Trial															74.12	18.89	20.97	50.49	75.11

Sinopep Allsino Bio Pharmaceutical Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥165 Mil.

Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinopep Allsino Bio Pharmaceutical Co Ltd (SHSE:688076) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 28, Linpu Road, Economic and Technological Development Zone, Jiangsu Province, Lianyungang, CHN, 222069

Website

http://www.sinopep.com.cn

Sinopep Allsino Bio Pharmaceutical Co Ltd is a market-oriented, research and development and innovation-driven biomedical enterprise focusing on the research, development, production and sales of peptide drugs and small molecule chemical drugs.

Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076) Headlines

No Headlines